After the establishment of TKI-based therapy in Ph+ ALL, studies on relapsed disease have revealed the frequent occurrence of point mutations in the BCR-ABL1 kinase domain (KD) [1,76]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.